ILARIS

Opinions on drugs - Posted on Jul 23 2014

Reason for request

Extension of indication

Clinical Benefit

Substantial

Substantial in the treatment of SJIA.

Clinical Added Value

moderate

Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.